Fig. 1 · Structure

Documents & Downloads

Afatinib

Cat. No. A18014 CAS 850140-72-6

EGFR inhibitor

Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

In Stock

Publications for Afatinib

1 publication citing this product

  1. Hui-Ju Huang, .et al. , Exp Biol Med (Maywood), 2025, May 15;250:10554 PMID: 40444141

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Afatinib (BIBW2992) inhibits EGFR and HER2 kinase activity. A cell-free assay reported IC50 values of 0.5 nM for wild-type EGFR, 0.4 nM for EGFR L858R, 10 nM for EGFR L858R/T790M and 14 nM for HER2. These biochemical endpoints should be distinguished from cellular potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
EGFR IC50 0.5 nM
HER2 IC50 14 nM
EGFR(L858R) IC50 0.4 nM
EGFR(L858R/T790M) IC50 10 nM

Afatinib Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Afatinib from 3 published references. In vitro models include NSCLC and HER2-amplified breast cancer cell-line panel. In vivo models include female six-week-old NOD/SCID mice bearing H2170 or H1781 xenografts.

Afatinib In Vitro Studies

In a 72 h MTS panel, afatinib inhibited HER2-altered lung cancer cells, with IC50 values of 0.140 μM (H2170), 0.086 μM (Calu-3) and 0.039 μM (H1781). KRAS-mutant A549, NRAS-mutant H1299 and MET-amplified H1993 were less sensitive. Responses depended on the model and assay. [2]

In primary rat cortical neurons, simultaneous afatinib (10 nM) co-treatment attenuated cytotoxicity caused by hemin (30 μM) after 16 h in an LDH assay. This culture result supports investigation of injury-associated signaling; it does not establish in vivo neuroprotection. [3]

Cell-free inhibition of EGFR and HER2 kinases

Biochemical assay · Human wild-type EGFR, EGFR L858R, EGFR L858R/T790M and HER2 kinase domains [1]

BIBW2992 inhibited EGFR variants and HER2 in a comparative enzyme panel. These assay IC50 values do not specify cellular treatment doses or establish covalent binding by themselves.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wild-type EGFR kinase inhibitionIC50 0.5 nM[1]
EGFR L858R kinase inhibitionIC50 0.4 nM[1]
EGFR L858R/T790M kinase inhibitionIC50 10 nM[1]
HER2 kinase inhibitionIC50 14 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial inhibitor dilutions; IC50 endpoints reported separately.
Exposure duration
30 min kinase reaction at room temperature (readable supplementary assay text).
Method
Kinase activity measured with or without inhibitor; comparator inhibitors included lapatinib, canertinib and gefitinib.
Vehicle
Inhibitor dilutions prepared in 50% Me2SO; this is the dilution solvent, not the final assay percentage.
Reported limits
Exact tested concentration series and numerical independent-experiment count are not specified in Table 1. Full supplement not parsed; no wider selectivity claim adopted.
Methods and source locations

Compound reported in the paper: Afatinib; Compound label in the paper: BIBW2992

Compound-level evidence; no salt conversion, catalog-number match or current Adooq lot validation is established.

Table 1 and its footnote; Results: BIBW2992 inhibits EGFR and HER2 kinase activity in vitro; Methods: Synthesis of compounds and In vitro kinase activity assays

Wild-type EGFR kinase inhibition: Cell-free kinase assay with pEY substrate; Table 1 states independent confirmation, without a numerical experiment count or uncertainty. — Table 1, BIBW2992 column and footnote

EGFR L858R kinase inhibition: Cell-free kinase assay with pEY substrate; Table 1 states independent confirmation, without a numerical experiment count or uncertainty. — Table 1, BIBW2992 column and footnote

EGFR L858R/T790M kinase inhibition: Cell-free kinase assay with pEY substrate; Table 1 states independent confirmation, without a numerical experiment count or uncertainty. — Table 1, BIBW2992 column and footnote

HER2 kinase inhibition: Cell-free kinase assay with pEY substrate; Table 1 states independent confirmation, without a numerical experiment count or uncertainty. — Table 1, BIBW2992 column and footnote

Growth inhibition across molecularly defined cancer cell lines

Cell-based study · NSCLC and HER2-amplified breast cancer cell-line panel [2]

The 72 h MTS assay showed stronger responses in HER2-altered lines than in the KRAS-mutant, NRAS-mutant and MET-amplified comparison lines. H1975 had an afatinib IC50 of 0.713 μM in this assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HER2-amplified H2170 proliferation inhibitionIC50 0.140 μM[2]
HER2-amplified Calu-3 proliferation inhibitionIC50 0.086 μM[2]
HER2 G776VC-mutant H1781 proliferation inhibitionIC50 0.039 μM[2]
EGFR exon 19-deleted HCC827 proliferation inhibitionIC50 0.001 μM[2]
EGFR L858R/T790M H1975 proliferation inhibitionIC50 0.713 μM[2]
KRAS-mutant A549 proliferation inhibitionIC50 5.275 μM[2]
NRAS-mutant H1299 proliferation inhibitionIC50 4.667 μM[2]
MET-amplified H1993 proliferation inhibitionIC50 2.309 μM[2]
HER2-amplified SK-BR-3 proliferation inhibitionIC50 0.002 μM[2]
HER2-amplified BT-474 proliferation inhibitionIC50 0.002 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; IC50 values are endpoints.
Exposure duration
72 h
Method
Modified MTS assay (CellTiter 96 Aqueous One Solution); untreated cells and gefitinib comparator.
Reported limits
Vehicle, exact replicate count and uncertainty on individual tabulated IC50 estimates are not specified in the read assay description; Figure 2a uses SD bars.
Methods and source locations

Compound reported in the paper: Afatinib; Compound label in the paper: Afatinib

Compound-level evidence; no salt conversion, catalog-number match or current Adooq lot validation is established.

Table 1; Figure 2a/caption; Methods: Cell lines and reagents and Cell growth inhibition assay; Results: Afatinib inhibits growth of both HER2-amplified and HER2-mutant lung cancer cells

HER2-amplified H2170 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

HER2-amplified Calu-3 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

HER2 G776VC-mutant H1781 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

EGFR exon 19-deleted HCC827 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

EGFR L858R/T790M H1975 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

KRAS-mutant A549 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

NRAS-mutant H1299 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

MET-amplified H1993 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

HER2-amplified SK-BR-3 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

HER2-amplified BT-474 proliferation inhibition: Modified MTS assay, 72 h drug exposure; untreated comparison. — Table 1, Afatinib column; Cell growth inhibition assay

Afatinib co-treatment in hemin-exposed cortical neurons

Cell-based study · Primary cultured cortical neurons from embryonic day 17 Sprague-Dawley rat brains [3]

Simultaneous afatinib treatment reduced hemin-associated LDH cytotoxicity at 16 h. Figure 1B reports mean ± S.E.M., n = 3 per group, with P < 0.05 for hemin plus afatinib versus hemin alone; injury was not eliminated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LDH cytotoxicity: hemin plus afatinib versus hemin aloneStatistical comparison P < 0.05; mean ± S.E.M.; n = 3/each group[3]

Literature-Reported Treatment Conditions

Treatment concentration
Afatinib 10 nM; hemin 30 μM
Exposure duration
16 h
Method
Simultaneous co-incubation; LDH release assay. Groups: vehicle, hemin, hemin plus afatinib, afatinib alone.
Vehicle
Afatinib stock in DMSO, diluted with DMEM or Neurobasal medium; final DMSO percentage not specified.
Co-treatment
Hemin is the injury challenge, not a second antitumor drug.
Reported limits
n = 3 per group is reported without establishing whether independent litters or cultures are the experimental units. No delayed-treatment or in vivo neuroprotection claim is supported.
Methods and source locations

Compound reported in the paper: Afatinib; Compound label in the paper: Afatinib

Compound-level evidence; no salt conversion, catalog-number match or current Adooq lot validation is established.

Figure 1B and caption; Methods: Chemicals, Primary culture of cortical neurons, Cytotoxicity assay and Statistics; Results: Afatinib attenuated hemin-induced neuronal death

LDH cytotoxicity: hemin plus afatinib versus hemin alone: LDH release relative to 0.1% Triton X-100 lysis control set at 100%; one-way ANOVA followed by LSD post-hoc test. — Figure 1B/caption; Cytotoxicity assay; Statistics

Afatinib In Vivo Studies

In vehicle-controlled H2170 and H1781 xenografts in NOD/SCID mice, oral afatinib at 20 mg/kg once daily, 6 days per week for 4 weeks suppressed tumor growth. H2170 showed stronger regression; H1781 retained residual growth. These results are specific to the tested HER2-altered models. [2]

Afatinib monotherapy in HER2-altered lung cancer xenografts

Animal study · Female six-week-old NOD/SCID mice bearing H2170 or H1781 xenografts [2]

Afatinib suppressed tumor growth relative to vehicle in both models. H2170 showed stronger regression, while H1781 tumors retained residual growth. Figure 4 reports mean ± SE, n = 8, and P < 0.05 versus vehicle by repeated-measures two-way ANOVA.

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily, 6 days per week
Treatment course
4 weeks
Vehicle
0.5 w/v (%) methyl cellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
H2170 (HER2 amplification)
20 mg/kg
Vehicle; randomized after tumors exceeded approximately 50 mm³Tumor regression and growth suppression relative to vehicle; mean ± SE, n = 8; P < 0.05. No exact tumor-volume values inferred from the curve.[2]
H1781 (HER2 G776VC mutation)
20 mg/kg
Vehicle; randomized after tumors exceeded approximately 50 mm³Tumor growth suppression relative to vehicle, with residual growth; mean ± SE, n = 8; P < 0.05. No exact tumor-volume values inferred from the curve.[2]
H2170 (HER2 amplification)
Model: Female NOD/SCID mice with H2170 (HER2 amplification) xenografts
Reported limits: Blinding and pharmacokinetic exposure not stated in the selected description.
H1781 (HER2 G776VC mutation)
Model: Female NOD/SCID mice with H1781 (HER2 G776VC mutation) xenografts
Reported limits: Blinding and pharmacokinetic exposure not stated in the selected description.
Methods and source locations

Compound reported in the paper: Afatinib; Compound label in the paper: Afatinib

Compound-level evidence; no salt conversion, catalog-number match or current Adooq lot validation is established.

Figure 4a–d/caption; Methods: Xenograft model and Statistical analysis; Results: antitumor effect in xenograft model

H2170 (HER2 amplification) · Figure 4a,b and caption; Methods: Xenograft model

H1781 (HER2 G776VC mutation) · Figure 4c,d and caption; Methods: Xenograft model

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 850140-72-6
Applications EGFR inhibitor
Formula C24H25ClFN5O3
Molecular Weight 485.94
Synonyms BIBW 2992
SMILES
O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (185.21 mM)
Water Insoluble
Ethanol 14 mg/mL (28.8 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Afatinib Research References

  1. [1] D Li, L Ambrogio, T Shimamura, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene (2008). PMID: 18408761 DOI: 10.1038/onc.2008.109 Source material
  2. [2] Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, et al. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER 2 oncogene alterations Cancer Science (2016). PMID: 26545934 DOI: 10.1111/cas.12845 Source material
  3. [3] Hui-Ju Huang, Yang-Jie Tseng, I-Jung Lee, et al. Involvement of EGFR-AKT signaling in hemin-induced neurotoxicity Experimental Biology and Medicine (2025). PMID: 40444141 DOI: 10.3389/ebm.2025.10554 Source material

Publications

1 publication citing this product

  1. Hui-Ju Huang, .et al. , Exp Biol Med (Maywood), 2025, May 15;250:10554 PMID: 40444141

Added to your cart

View Cart Checkout
Loading...